← Back

NovoCure: Novocure's Q2 2025: Revenue Growth and Clinical Progress

Novocure reported net revenues of $159 million for the second quarter of 2025, a 6% increase from the same quarter last year. This growth was driven by a 7% year-over-year active patient growth in the GBM franchise, including double-digit growth in international markets. The company's gross margin for the quarter was 74%, down from 77% in Q2 2024, primarily due to the rollout of the HFE array and the launch of non-small cell lung cancer. The net loss for the quarter was $40 million, with a loss per share of $0.36, beating analysts' estimates of $-0.39. Adjusted EBITDA was negative $10 million.

NVCR

USD 12.93

-0.31%

A-Score: 2.8/10

Publication date: July 25, 2025

Author: Analystock.ai

📋 Highlights
  • Net Revenue Growth $159 million, up 6% year-over-year, driven by 7% active patient growth in GBM franchise.
  • Optune Lua Performance Generated $2.4 million in net revenues, with $1.1 million from non-small cell lung cancer.
  • Gross Margin Decline 74% gross margin, down from 77% in Q2 2024, due to HFE array rollout and NSCLC launch.
  • Commercial Expansion 121 NSCLC prescriptions (106 in U.S., 15 in Germany) and 137 Optune Lua patients globally.
  • Clinical Trial Success PANOVA-3 trial showed 16.2 months median overall survival, a 2-month improvement over control arm.

Financial Performance

The company's commercial business grew, with 121 prescriptions for non-small cell lung cancer, 106 in the U.S. and 15 in Germany. There were 137 Optune Lua patients globally, 94 from non-small cell lung cancer and 43 from MPM. The company received positive feedback from physicians on Optune Lua, with 75 unique prescribers, 41 new to Tumor Treating Fields therapy. Novocure's R&D expenses were $63 million, a 2% increase from Q2 of 2024. Sales and marketing expenses were $57 million, a 1% increase from Q2 of last year. G&A expenses were $44 million, a 17% increase from Q2 of 2024, driven by higher share-based compensation expenses and personnel costs.

Clinical Developments

Recent clinical developments include the PANOVA-3 trial, which demonstrated a median overall survival of 16.2 months, 2 months greater than the control arm, in unresectable locally advanced pancreatic cancer patients treated with TTFields therapy, gemcitabine, and nab-paclitaxel. The company expects to file the PMA with the FDA in the third quarter for pancreatic cancer and has submitted the first two PMA modules for brain metastases from non-small cell lung cancer. The METIS trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for patients treated with TTFields therapy.

Valuation and Outlook

Novocure's valuation metrics suggest that the stock is trading at a discount. The P/S ratio is 2.07, and the EV/EBITDA is -16.72. According to analysts, the stock has a potential upside, with estimated revenue growth at 7.2% for next year. The company is positioning Optune Lua as a treatment option for patients with non-small cell lung cancer who have progressed beyond platinum-based therapy. With a cash and investment balance of $912 million and $560 million in convertible notes due later this year, Novocure has a solid financial position to execute on its growth strategy.

NovoCure's A-Score